Cytosine
About
What does Cytosine do?
Cytosine is building an AI platform designed to automate the entire lifecycle of AI model development, from data preparation to deployment and monitoring. Their goal is to significantly reduce the time, cost, and expertise required to build and manage sophisticated AI models, making advanced AI more accessible to businesses.
When was Cytosine founded?
Cytosine was founded in 2026.
What industry does Cytosine operate in?
Cytosine operates in MLOps, DataOps, AI Infrastructure, Foundation Model, Generative AI, API Platform.
Discover AI evaluation tools that automate feedback and enhance performance assessments. Subscribe for updates on our innovative platform!
AxLoop AI provides fleet observability for AI agents, instrumenting every MCP tool call on every device within an organization's perimeter.
Ctxlayer provides human-in-the-loop context engineering and curation tools for AI-assisted development, enabling AI agents to access consistent, curated domain intelligence.
Ashr provides a test and evaluation platform for AI agents, generating synthetic user stories to identify errors and ensure quality across various modalities.
A working archive of production AI products, agentic platforms, and operating systems, with product notes, systems work, and practical AI research.
Axiora Labs accelerates business growth with enterprise AI consulting, intelligent automation, custom AI solutions, and AI product engineering.
Korteza is an AI consultancy and implementation firm that helps enterprises move AI models from experimental stages to production-grade systems, focusing on data ownership and secure, private deployments.
Spikevision develops AI-powered visual inspection solutions for industrial quality control.
An entrant is a company tagged MLOps whose domain was first registered in the window, counted from registry records in the StartupHub directory. 8 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.